Search

Your search keyword '"Chiaravalloti, Agostino"' showing total 23 results
Start Over Author "Chiaravalloti, Agostino" Publisher mdpi ag
23 results on '"Chiaravalloti, Agostino"'

4. Complementary Role of Combined Indirect and Direct Cardiac Sympathetic (Hyper)Activity Assessment in Patients with Heart Failure by Spectral Analysis of Heart Rate Variability and Nuclear Imaging: Possible Application in the Evaluation of Exercise Training Effects

Author

Iellamo, Ferdinando, primary, Perrone, Marco Alfonso, additional, Cimini, Andrea, additional, Caminiti, Giuseppe, additional, Chiaravalloti, Agostino, additional, Parisi, Attilio, additional, and Schillaci, Orazio, additional

Published
2022
Full Text
View/download PDF

11. High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse

Author

Assanto, Giovanni Manfredi, primary, Ciotti, Giulia, additional, Brescini, Mattia, additional, De Luca, Maria Lucia, additional, Annechini, Giorgia, additional, D’Elia, Gianna Maria, additional, Agrippino, Roberta, additional, Del Giudice, Ilaria, additional, Martelli, Maurizio, additional, Chiaravalloti, Agostino, additional, and Pulsoni, Alessandro, additional

Published
2021
Full Text
View/download PDF

12. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

Author

Filippi, Luca, primary, Frantellizzi, Viviana, additional, Chiaravalloti, Agostino, additional, Pontico, Mariano, additional, De Feo, Maria Silvia, additional, Corica, Ferdinando, additional, Montebello, Melissa, additional, Schillaci, Orazio, additional, De Vincentis, Giuseppe, additional, and Bagni, Oreste, additional

Published
2021
Full Text
View/download PDF

14. Levels and Factors Associated with Resilience in Italian Healthcare Professionals during the COVID-19 Pandemic: A Web-Based Survey

Author

Lisi, Lucia, primary, Ciaffi, Jacopo, additional, Bruni, Antonella, additional, Mancarella, Luana, additional, Brusi, Veronica, additional, Gramegna, Pasquale, additional, Ripamonti, Claudio, additional, Quaranta, Elisabetta, additional, Borlandelli, Elena, additional, Gallo, Gaetano, additional, Garofalo, Eugenio, additional, Chiaravalloti, Agostino, additional, Viola, Pasquale, additional, Ruscitti, Piero, additional, Caio, Giacomo, additional, D’Onghia, Martina, additional, D’Amuri, Andrea, additional, Cimellaro, Antonio, additional, Facchini, Giancarlo, additional, La Regina, Micaela, additional, Spinardi, Luca, additional, De Giorgio, Roberto, additional, Giacomelli, Roberto, additional, Landini, Maria Paola, additional, Berardi, Domenico, additional, Meliconi, Riccardo, additional, and Ursini, Francesco, additional

Published
2020
Full Text
View/download PDF

20. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study

Author

Albano, Domenico, primary, Laudicella, Riccardo, additional, Ferro, Paola, additional, Allocca, Michela, additional, Abenavoli, Elisabetta, additional, Buschiazzo, Ambra, additional, Castellino, Alessia, additional, Chiaravalloti, Agostino, additional, Cuccaro, Annarosa, additional, Cuppari, Lea, additional, Durmo, Rexhep, additional, Evangelista, Laura, additional, Frantellizzi, Viviana, additional, Kovalchuk, Sofya, additional, Linguanti, Flavia, additional, Santo, Giulia, additional, Bauckneht, Matteo, additional, and Annunziata, Salvatore, additional

Published
2019
Full Text
View/download PDF

21. Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer's Disease: A CSF/ 18 F-FDG-PET Study.

Author

Bonomi CG, Chiaravalloti A, Camedda R, Ricci F, Mercuri NB, Schillaci O, Koch G, Martorana A, and Motta C

Abstract

Glial and microglial cells contribute to brain glucose consumption and could actively participate in shaping patterns of brain hypometabolism. Here, we aimed to investigate the association between 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake and markers of microglial and astrocytic activity in a cohort of patients with Alzheimer's Disease (AD). We dosed cerebrospinal fluid (CSF) levels of soluble Triggering Receptor Expressed on Myeloid cells (sTREM2), Glial Fibrillary Acidic Protein (GFAP), a marker of reactive astrogliosis, and β-S100, a calcium-binding protein associated with a neurotoxic astrocytic profile. No associations were found between sTREM-2 and 18F-FDG uptake. Instead, 18 F-FDG uptake was associated negatively with CSF β-S100 in the left supramarginal gyrus, inferior parietal lobe and middle temporal gyrus (Brodmann Areas (BA) 21 and 40). Increased β-S100 levels could negatively regulate neuronal activity in the temporo-parietal cortex to prevent damage associated with AD hyperactivity, or rather they could reflect neurotoxic astrocytic activation contributing to AD progression in key strategic areas. We also identified a trend of positive association of 18 F-FDG uptake with CSF GFAP in the right fronto-medial and precentral gyri (BA 6, 9 and 11), which has been reported in early AD and could either be persisting as an epiphenomenon tied to disease progression or be specifically aimed at preserving functions in the frontal cortex. Overall, CSF markers of astrogliosis seem to correlate with cortical glucose uptake in symptomatic sporadic AD, highlighting the role of astrocytes in shaping regional hypometabolism and possibly clinical presentation.

Published
2023
Full Text
View/download PDF

22. Detection Rate and Clinical Impact of PET/CT with 18 F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study.

Author

Filippi L, Bagni O, Crisafulli C, Cerio I, Brunotti G, Chiaravalloti A, Schillaci O, and Dore F

Abstract

Our aim was to assess the detection rate (DR) of positron emission computed tomography (PET/CT) with anti-1-amino-3-[ 18 F]-flurocyclobutane-1-carboxylic acid ( 18 F-FACBC) in patients with biochemical recurrence (BCR) from prostate cancer (PC). As a secondary endpoint, we evaluated 18 F-FACBC PET/CT's impact on patients management. Clinical records of 81 patients submitted to 18 F-FACBC PET/CT due to PC BCR in two Italian Nuclear Medicine Units were retrospectively assessed. DR was gauged in the whole cohort and stratifying patients by discrete intervals of PSA levels. PET/CT's impact on clinical management was scored as (1) major if it entailed an intermodality change (e.g., from systemic to loco-regional therapy); (2) minor if it led to an intramodality change (e.g., modified radiotherapy field). PET/CT's DR resulted in 76.9% in the whole cohort, with a positive predictive value of 96.7%. Stratified by PSA quartile intervals, PET/CT's DR was 66.7%, 71.4%, 78.9% and 90% for PSA 0.2-0.57 ng/mL, 0.58-0.99 ng/mL, 1-1.5 ng/mL and >1.5 ng/mL without significant difference among groups ( p = 0.81). The most common sites of relapse were prostate bed and pelvic lymph nodes (59.3%). PET/CT impacted on clinical management in 33/81 cases (40.7%), leading to a major change in 30 subjects (90.9%). 18 F-FACBC PET/CT localized recurrence in patients with BCR, with meaningful DR also at low PSA levels and significantly impacted on clinical management.

Published
2022
Full Text
View/download PDF

23. Prognostic Value of 18 F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223.

Author

Filippi L, Spinelli GP, Chiaravalloti A, Schillaci O, Equitani F, and Bagni O

Abstract

We aimed to investigate the role of positron emission computed tomography (PET/CT) with 18 F-choline for predicting the outcome of metastatic castration-resistant prostate cancer (mCRPC) submitted to treatment with Radium-223 ( 223 Ra-therapy). Clinical records of 20 mCRPC patients submitted to PET/CT with 18 F-choline before 223 Ra-therapy were retrospectively evaluated. The following PET-derived parameters were calculated: number of lesions, maximum and mean standardized uptake values (SUVmax, SUVmean), lean body mass corrected SUV peak (SULpeak), metabolic tumor volume (MATV), and total lesion activity (TLA). After 223 Ra-therapy, all patients underwent regular follow-up until death. The predictive power of clinical and PET-derived parameters on overall survival (OS) was assessed by Kaplan-Meier analysis and the Cox proportional hazard method. All the patients showed 18 F-choline-avid lesions at baseline PET/CT. Among the enrolled subjects, eleven (55%) completed all the six scheduled cycles of 223 Ra-therapy; seven (35%) were responders according to imaging and biochemical parameters. Mean OS was 12.7 ± 1.4 months: by Kaplan-Meier analysis, number of lesions, PSA level and TLA were significantly correlated with OS. In multivariate Cox analysis, TLA remained the only significant predictor of survival ( p = 0.003; hazard ratio = 7.6, 95% confidence interval = 1.9-29.5 months). 18 F-choline PET may be useful for patients' stratification before 223 Ra-therapy. In particular, high metabolically active tumor burden (i.e., TLA) was predictive of poor outcome.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results